Redeye comments on Lipigon’s third quarter report 2024. The same day as the report was released, the company communicated the enrolment of the first patient in the ongoing phase II study of Lipisense.
ANNONS
Redeye comments on Lipigon’s third quarter report 2024. The same day as the report was released, the company communicated the enrolment of the first patient in the ongoing phase II study of Lipisense.